Osteomalacia is a well-recognised complication of liver disease especially in those with chronic cholestasis such as primary biliary atresia (PBA) and primary biliary cirrhosis (PBC) (Atkinson et al., 1956; Glasgow et al., 1976) . In PBC, low levels of plasma 250HD have been reported (Long et al., 1976; Wagonfeld et al., 1976) but the effect of cholestasis on vitamin D metabolism as distinct from that of hepatocellular dysfunction has yet to be clearly defined. The importance of cholestasis in the development of rickets is well illustrated in PBA where relief of the obstruction results in both a rise in the plasma 25 hydroxycholecalciferol (250HD) and healing of the rickets, despite the continuing presence of biliary cirrhosis (Daum et al., 1976) .
Animal experiments have suggested that 'Address for correspondence and reprint requests: Dr R. T. Jung, Addenbrooke's Hospital, Trumpington Street, Cambridge, England. Received for publication 10 April 1979 cholestasis may affect 25 hydroxylation. Thus 25 hydroxylase activity as measured in rat liver homogenates is reduced by bile duct ligation for 21 days or by the addition of bile salts (Bolt et al., (1978) . The finding in patients with PBC of a subnormal rise in plasma 250HD after the administration of parenteral vitamin D2 has suggested an impairment of 25 hydroxylation (Wagonfeld et al., 1976) ; but a recent tracer study also in patients with PBC has shown no abnormality in the conversion of 3H cholecalciferol (3HD3) to 3H 250HD (Krawitt et al., 1977) . To investigate further the effect of cholestasis on 25 hydroxylation in man we have studied the metabolism of intravenously injected 3HD3 in patients with acute cholestasis due to extrahepatic bile duct obstruction as well as in patients with chronic cholestasis (PBC). Malabsorption of vitamin D does occur in PBC (Krawitt et al., 1977) but this is unlikely to be a major cause of the low plasma 250HD in this condition, as ultra-violet light is the more important source of vitamin D in man (Preece et al., 1975; Pittet et al., 1979; Poskitt et al., 1979) . We have therefore also investigated the response of jaundiced patients with PBC to ultra-violet irradiation.
It has also been reported that the urinary excretion of tritium (3H) after the injection of 3HD3 was increased in jaundiced patients with PBC; preliminary work suggested that this did not represent an increased excretion of 250HD (Krawitt et al., 1977) . We have further investigated this possibility by studying the urinary 3H excretion after the injection, on separate occasions, of 3HD3 and 3H 250HD3 in patients with acute and chronic cholestasis.
Methods
Eight patients with PBC proven by liver biopsy and six patients with acute extrahepatic obstructive jaundice were studied. The patients with PBC were all female, had a mean age of 55-9 ±13-7 years (±SD) and had had symptoms for 25-5 ±24-1 months. Three of these patients were receiving supplementary vitamin D. The group with acute extrahepatic obstructive jaundice consisted of three male and three female subjects with a mean age of 63-8 ±9-5 years and had experienced symptoms for 1-0 ± 1-3 months. Three had carcinoma of the pancreas and three had gallstones.
All investigations were performed after approval by Addenbrooke's Hospital Ethical Committee and after fully informed consent had been obtained from the patients.
Dietary vitamin D intake was assessed by the recall technique (Burke, 1947) . Bone biopsies were obtained from the iliac crest using a trephine needle in six patients with PBC. A bone biopsy was considered normal if there was an osteoid area of less than 5 % with normal calcification fronts (Woods et al., 1968 (Edelstein et al., 1974) . 25 hydroxyvitamin D binding protein (25OHDBP) was assayed by immunoelectrophoresis using anti-Gc globulin (DAKO). This protein is now believed to be the same as Gc globulin (Bouillon et al., 1976) and the Dako antibody used has been shown to react only against the 25OHDBP (Dann, J. G., personal communication). Vitamin D3 halflife and 250HD production were measured as previously described (Jung et al., 1978) . Calcium absorption was measured by a forearm counting technique after seven days on a 10 mmol (400 mg) calcium diet (Chalmers et al., 1973 Response to ultra-violet light was assessed in four female control subjects and three patients with PBC. A total of 20 minutes' whole body exposure was given over four weeks using four Westinghouse FS40 lamps. One patient (see Table 2 , PBC subject 3) aged 65 with Stage IV PBC (Scheuer, 1973) was studied in detail during ultra-violet light exposure with 3HD3 half-life measurements before and after ultra-violet irradiation.
Results BIOCHEMICAL FINDINGS Table 1 shows the biochemical findings in the patients with PBC and extrahepatic obstructive Previous studies have shown that in a normal population there is a negative correlation between the 3HD3 clearance from plasma and the plasma 250HD (Jung et al., 1978) . In the patients with acute obstruction, the 3HD3 half-life was appropriate to the plasma 250HD level. Most of the patients with PBC also had an appropriate response, but two subjects, both with very low plasma 250HD levels, had a 3HD3 half-life longer than expected. The appearance of 3H 250HD in the plasma four hours after the injection of 3HD3 was also measured (Fig.  1) and in normal subjects a negative correlation exists between this and the vitamin 3HD3 half-life (r= -0-68) (Jung et al., 1978) . All (Fig. 2) . Most patients excreted less than 3% of the injected dose of 3H 250HD3 but two people with serum bilirubins of 145 and 62 ,umol/l (8-5 and 3-6 mg/100 ml) excreted 4-5 % and 3-6 % respectively.
ULTRA-VIOLET LIGHT
The response to ultra-violet light was examined in three patients with PBC (Table 2) , two with severe jaundice and one with a slightly raised bilirubin. All three patients demonstrated a rise of plasma 250HD similar to that seen in four normal subjects, the greatest rise occurring in the patient with the lowest initial plasma 250HD level. This patient was studied in detail (Fig. 3) . Bone biopsy showed no evidence of osteomalacia. The serum calcium was 1-98 mmol/I (7-9 mg/100 ml) albumin 25 g/l, phosphate 0-85 mmol/l (2-6 mg/100 ml), bilirubin 116 [.mol/l (6-8 mg/100 ml), alkaline phosphatase 148 IU/l, and plasma 250HD 4.3 nmol/l (1-7 pg/l). The plasma 250HD level rose rapidly after starting ultra-violet therapy and was accompanied by a rise in serum calcium, phosphate, and alkaline phosphatase. 3H vitamin D half-life was 15-0 hours initially and rose to 30 hours after therapy. The percentage of 3H 250HD appearing at four hours after the injection of 3HD3 was 46-7% before ultra-violet light and 8-9 % after treatment; a similar response to that seen in normal subjects before and after exposure to ultra-violet light.
Discussion
Despite the low levels of plasma 250HD in our patients with PBC none showed evidence of osteomalacia on bone histology or radiology. This contrasts with other reports in which the incidence of osteomalacia in PBC has varied from 8 to 83 % (mean=30-6%) (Table 3 ). This wide variation in incidence may be due to the different histological criteria used for the diagnosis of osteomalacia. As osteoid increases with age (Bordier and Tun Chot, 1972) , care must be taken in interpreting the osteoid measurements, as in most reported series the mean age of the patients with PBC was over 50 years. The present work demonstrates that 3H 250HD production from injected 3HD3 is normal in all patients with acute obstructive jaundice and the majority of patients with PBC. Although this observation confirms a previous report of normal 25 hydroxylation in PBC (Krawitt et al., 1977) , it is at variance with the finding of a 48 % reduction in 25 hydroxylase activity in liver homogenates from rats in which the bile duct had been ligated for 21 days (Bolt et al., 1978) . This difference may well represent species variation. We found normal 25 hydroxylation in two patients with acute bile duct obstruction who had serum bilirubin levels of 300 and 360 ,umol/l. Moreover, in PBC plasma 250HD was not correlated with biochemical indices of hepatic function. The low 250HD production found in two patients with PBC could indicate an impairment of 25 hydroxylation due to liver disease. An alternative explanation, as both were receiving supplementary vitamin D, is that it was due to a forward negative effect of a high liver vitamin D level on 25 hydroxylation .
The fact that acute cholestasis does not result in a rapid reduction in the plasma 250HD suggests that the reduced plasma 250HD in PBC is related to the duration of cholestasis rather than to the severity of liver damage. It is unlikely that the low level of 25OHDBP found in patients with acute and chronic cholestasis is a cause of low plasma 250HD as this binding protein is only 2-3% saturated in normal subjects and thus has a considerable reserve of binding capacity even in a reduced concentration (Haddad and Walgate, 1976) .
We have confirmed the finding that the urinary excretion of 3H after the injection of 3HD3 in PBC correlates with the serum bilirubin (Krawitt et al., 1977 Arnaud et al. (1975) have reported that, in man, after an injection of (26-273H) 250HD, a third of the radioactivity appeared in duodenal aspirates within 24 hours. Results suggestive of an enterohepatic circulation of 250HD have been found in rats (Sitrin et al., 1978) and rhesus monkeys (Rikkers, 1975) . However, additional work is necessary to characterise the nature of the radioactivity appearing in bile after 3H 250HD3 injection and the significance of a possible enterohepatic circulation of 250HD in man.
As the plasma clearance and hydroxylation of 3HD3 is normal, the low plasma 250HD of chronic cholestasis may be due to a reduction in the input of vitamin D. We did find dietary intake of vitamin D to be low in PBC and absorption of vitamin D is likely to have been impaired in the presence of steatorrhoea (mean faecal fat was 54 8 ±6 9 mmol per 24 hours). However, this low dietary intake would be important only if exposure or response to ultra-violet light were reduced, as the major source of vitamin D in man is ultra-violet irradiation. It has recently been shown that the ingestion of 200 IU of vitamin D2 per day for one month did not raise the plasma 250HD significantly, whereas irradiation of 600 cm2 of skin for five minutes produced a significant increase in the plasma 250HD (Poskitt et al., 1979; Davie and Lawson, in preparation) . Also, plasma 250HD has been shown to be significantly reduced in sailors submerged in nuclear submarines for several months despite adequate dietary intake of vitamin D (Preece et al., 1975) . Fractionation studies on plasma 250HD have shown that 84% of the total plasma 250HD is 250HD3, presumably derived mostly from sunlight (Haddad and Hahn, 1973) .
We found a normal response to ultra-violet light in the three patients with BPC, despite a considerably raised serum bilirubin in two of the subjects. In the patient studied in detail, where the serum bilirubin was 116 ,umol/l (6-8 mg/100 ml), the rise in serum calcium and phosphate as well as in plasma 250HD suggested a low vitamin D reserve, although the bone biopsy showed no evidence of osteomalacia. 3H 250HD production from injected 3HD3 diminished appropriately as the plasma 250HD rose and 3HD3 half-life became longer, again emphasising the normal 25 hydroxylation in PBC, even though the initial plasma 250HD was low in this patient. The adequate response to ultra-violet light in these three patients suggests that the low 250HD in PBC is due to inadequate exposure to sunlight. We have no evidence that jaundice may raise the threshold of response to ultra-violet light but this possibility will need to be excluded by further quantitative studies.
We conclude that, in acute and chronic cholestasis, 25 hydroxylation is normal but 3H excretion in urine is increased after injection of 3HD3. Increased excretion of vitamin D metabolites may be sufficient to deplete vitamin D reserves if input is inadequate. Although oral intake and absorption of vitamin D are low in PBC, input from the skin should be sufficient to maintain reserves (as the response to ultra-violet light is normal) unless exposure to sunlight is also inadequate. It is likely, therefore, that the development of osteomalacia in PBC is multifactorial. As 25-and lox-hydroxylation (Long et al., 1978b) are normal, parenteral vitamin D or ultra-violet light should prevent osteomalacia in all cases.
Addendum
Since this manuscript was submitted for publication we have measured the urinary excretion of radioactivity after intravenous 3H250HD3 in an additional five jaundiced patients with acute biliary obstruction (two with complete obstruction). We have confirmed that very little radioactivity (less than 3 %) appears in the urine even at serum bilirubin concentration as high as 200 rmol/l (11-7 mg/100 ml).
